About company:-
Dr. Reddy's Laboratories is an Indian multinational drug company located in Hyderabad, Telangana, India. The company was founded by Anji Reddy, who had earlier worked in the Indian Institute of Drugs and Drugs Pharmaceuticals, Hyderabad, India. Dr. Reddy manufactures and markets various types of medicines in India and abroad. The company has 190 medicinal drugs, there are 60 active drug components (APIs) for drug production, diagnostic kits, serious care and biotechnology products.
Dr. Reddy started the supply of Indian medicines as a supplier, but soon he started exporting to other low-regulated markets, which had the benefit of not spending time and money on the production plant, which would be approved by the drug licensing agency. US Food and Drug Administration (FDA). In the early 1990s, due to its increased volume and profitability in these irregular markets, the company has been able to focus on obtaining approval for its formulations and large drug production plants in the more developed economy by the drug regulators. The US has allowed them to move in regulated markets like Europe and Europe. According to the Trust Research Advisory of the Brand Analytics Company, in 2014, according to the 2014 Brand Trust Report 2014, Dr. Reddy Laboratories was listed among the most trusted brands in India in 1200 list.
Until 2007, Dr Reddy had seven FDA plants and seven FDA-inspection and ISO 9001 (Quality) and ISO 14001 (Environmental Management) Certified Plants, were preparing patient-made medicines - out of which five are in India and two in the UK.
In 2010, family-controlled Dr. Reddy had denied the promise of developing a generic business in India. J. Reddy was blaming the company for violating patents as announced. A common version of atorvastatin, marketed by lipiter, anti-cholesterol, is used as a foicer. Reddy has been linked to UK Pharmaceuticals Multinational Glaxo SmithKline.
Company history:-
In 1984, Dr. In 1998, Reddy made active pharmaceutical ingredients. In 1986, Reddy started working on branded formulations. Within a year, Reddy's introduced the company's first known brand Norillet in the market. Soon, Dr. Reddy achieved another success in treating omease, its branded omeprazole - ulcer and reflex oesophagitis - at that time the Indian market was launched at half the price of other brands. This is now the branch in hyderabad.
Within a year, Reddy became the first Indian company to export active ingredients for pharmaceuticals in Europe. In 1987, Reddy started making manufacturers of pharmaceutical products from manufacturers of pharmaceuticals to other producers.
International expansion:-
The company's first international step was taken to Russia in 1992. There Reddy made a joint venture with the country's largest pharmaceutical manufacturer Biomed. With the help of Badmid's Chief Executive, Reddy's Labs was responsible for the loss of significant material due to Moscow's branch activity. Reddy sold joint ventures to the Kremlin-Friendly Systema Group. In 1993, Reddy entered the Middle East joint venture and made two formulation units in Russia. Reddy exported large amounts of large quantities of medicines to these units and later converted them into final products. In 1994, Reddy targeted American generic market by creating art manufacturing.
New drug discovery:-
Reddy has targeted specialized generic products to build the basis for finding drugs in Western markets in the search of new medicines. Specialty generic development is an important step for the company's growing interest in the development of new chemical organizations. Generally the values included in the laboratory innovations, developing areas and sending market sales teams are also at the development stage of new private drug development. Before creating Brand-New Drugs with specialty generics, the company allows them to gain experience with those steps.
Reddy has invested heavily in establishing R & D laboratories and is the only Indian company to make significant research and development abroad. In 1992, Reddy Research Foundation was established and Dr. R. First, the research was conducted to find out the correspondence of the foundation's drug research policy. New researchers, especially those who are studying abroad on doctoral and post-doctoral studies, have replaced Indian students into new research R & D. In 2000, the Foundation established American laboratories in Atlanta, which was dedicated to the discovery and design of the novel therapies. The laboratory is called Reddy US Therapics Inc. (RSTI) and its main objective is to research the next generation of drugs using genomics and proteins. Reddy's research focused largely on the Western market - anti-cancer, diabetes, cardiovascular disease and anticoagulant medicines.
Reddy's international marketing success was built on a strong production center, which has been the result of inadequate growth by the acquisition of international and national facilities. Reddy's merged Chemnor Drug Limited (CDL), the primary purpose of providing active medication material in North America and Europe's technically demanding market, This merger allowed Reddy to enter the value-added generic business in the regulated markets of the API.
Join WhatsApp
Join Telegram
